* index person has covid-19 symptoms for more than 5 days at enrolment * known past covid-19 or current infection confirmed by positive sars-cov-2 pcr test at enrolment * symptoms at enrolment indicating covid-19: increased body temperature or acute respiratory symptoms of any severity or newly occuring loss of taste or smell or ague or sumulatneously occuring headache and body ache * known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of driponin®) * known chronic obstructive pulmonary disease * known acute or chronic hepatitis b or c or other clinically recognizable or known liver dysfunction * known hiv infection or aids * known symptomatic allergic rhinitis * current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ass (including prophylactic use), metamizol) * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs * known or clinically suspected disturbance of the blood-brain-barrier (e.g., abcb-1 (=mdr1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (p-gp) * known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate * pregnancy or lactation * women of child-bearing potential planning to become pregnant or not using effective mehods of contraception * any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation * previous or planned (during next 14 days) vaccination with any covid-19 vaccine * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with ivermectin * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating covid-19 in alignemnt with rki * apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) * known alcohol or drug abuse * participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days * previous participation in this same clinical trial

* index person has covid-19 symptoms for more than 5 days at enrolment * known past covid-19 or current infection confirmed by positive sars-cov-2 pcr test at enrolment * symptoms at enrolment indicating covid-19: increased body temperature or acute respiratory symptoms of any severity or newly occuring loss of taste or smell or ague or sumulatneously occuring headache and body ache * known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of driponin®) * known chronic obstructive pulmonary disease * known acute or chronic hepatitis b or c or other clinically recognizable or known liver dysfunction * known hiv infection or aids * known symptomatic allergic rhinitis * current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ass (including prophylactic use), metamizol) * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs * known or clinically suspected disturbance of the blood-brain-barrier (e.g., abcb-1 (=mdr1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (p-gp) * known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate * pregnancy or lactation * women of child-bearing potential planning to become pregnant or not using effective mehods of contraception * any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation * previous or planned (during next 14 days) vaccination with any covid-19 vaccine * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with ivermectin * recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating covid-19 in alignemnt with rki * apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) * known alcohol or drug abuse * participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days * previous participation in this same clinical trial

- index person has covid-19 symptoms for more than 5 days at enrolment - known past covid-19 or current infection confirmed by positive sars-cov-2 pcr test at enrolment - symptoms at enrolment indicating covid-19: increased body temperature or acute respiratory symptoms of any severity or newly occuring loss of taste or smell or ague or sumulatneously occuring headache and body ache - known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of driponin®) - known chronic obstructive pulmonary disease - known acute or chronic hepatitis b or c or other clinically recognizable or known liver dysfunction - known hiv infection or aids - known symptomatic allergic rhinitis - current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ass (including prophylactic use), metamizol) - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs - known or clinically suspected disturbance of the blood-brain-barrier (e.g., abcb-1 (=mdr1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (p-gp) - known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate - pregnancy or lactation - women of child-bearing potential planning to become pregnant or not using effective mehods of contraception - any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation - previous or planned (during next 14 days) vaccination with any covid-19 vaccine - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with ivermectin - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating covid-19 in alignemnt with rki - apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) - known alcohol or drug abuse - participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days - previous participation in this same clinical trial

- index person has covid-19 symptoms for more than 5 days at enrolment - known past covid-19 or current infection confirmed by positive sars-cov-2 pcr test at enrolment - symptoms at enrolment indicating covid-19: increased body temperature or acute respiratory symptoms of any severity or newly occuring loss of taste or smell or ague or sumulatneously occuring headache and body ache - known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of driponin®) - known chronic obstructive pulmonary disease - known acute or chronic hepatitis b or c or other clinically recognizable or known liver dysfunction - known hiv infection or aids - known symptomatic allergic rhinitis - current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ass (including prophylactic use), metamizol) - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs - known or clinically suspected disturbance of the blood-brain-barrier (e.g., abcb-1 (=mdr1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (p-gp) - known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate - pregnancy or lactation - women of child-bearing potential planning to become pregnant or not using effective mehods of contraception - any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation - previous or planned (during next 14 days) vaccination with any covid-19 vaccine - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with ivermectin - recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating covid-19 in alignemnt with rki - apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) - known alcohol or drug abuse - participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days - previous participation in this same clinical trial